Results from the BIO-RESORT (TWENTE III) Trial Presented at TCT 2016 and Published Simultaneously in The Lancet
WASHINGTON – October 30, 2016 – Results of a large-scale, multicenter study found that treatment with two thin-strut drug-eluting stents were both non-inferior to a durable polymer drug-eluting stent and showed favorable clinical outcomes at one year in treating an all-comers population with a high proportion of patients with acute coronary syndromes.
Findings from the BIO-RESORT (TWENTE III) trial were reported today at the 28th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine. The study was also published simultaneously in The Lancet.
“In patients with coronary artery disease treated with durable polymer-coated drug-eluting stents, the life-long presence of the polymer may delay arterial healing and even cause adverse clinical events,” said Clemens von Birgelen, MD, PhD, Professor of Medicine at Thoraxcentrum Twente in Enschede, Netherlands. “Biodegradable polymer stents might improve long-term outcomes, but studies with early biodegradable polymer stents that had thick stainless steel struts (120 µm) showed equivocal results. However, very thin-strut (60–81µm) biodegradable polymer stents that have flexible designs and thin, refined coatings are now available.”
BIO-RESORT (TWENTE III) was a large-scale, investigator-initiated, assessor and patient-blinded, multicenter, three-arm trial that compared the safety and efficacy of two novel, very thin-strut biodegradable polymer stents to an established durable polymer stent (Resolute Integrity). Both biodegradable polymer stents have very thin struts but differ in the type, amount, distribution and degradation speed of their respective coating. The Synergy everolimus-eluting platinum chromium stent is the first and only biodegradable polymer drug-eluting stent approved by the FDA for clinical use in the United States and this was its first randomized assessment in an all-comers population. The Orsirio biodegradable polymer sirolimus-eluting cobalt chromium stent has been used clinically outside the United States.
Patients were randomly assigned (1:1:1) to treatment with the very thin-strut biodegradable polymer everolimus-eluting or sirolimus-eluting stents or the durable polymer zotarolimus-eluting stent at four sites in the Netherlands. The primary endpoint was a composite of safety (cardiac death or target-vessel-related myocardial infarction) and efficacy (target-vessel revascularization) at 12 months, analyzed by intention-to-treat (non-inferiority margin: 3.5%).
Of the 3,514 patients enrolled and analyzed, 2,449 (69.7%) had acute coronary syndromes, which included 1,073 (30.5%) ST-elevation myocardial infarctions. Twelve-month follow-up was available in 3,490 (99.3%) patients. The primary endpoint was met by 4.7% (55/1,172) of patients assigned to everolimus-eluting stents, 4.7% (55/1,169) assigned to sirolimus-eluting stents and 5.4% (63/1,173) assigned to zotarolimus-eluting stents. The non-inferiority of the everolimus-eluting stent and the sirolimus-eluting stent was confirmed (both: -0.7% absolute risk difference, 95% CI:-2.4–1.1; upper limit of 1-sided 95% CI: 0.8%, Pnon-inferiority<0.0001). Definite stent thrombosis (ARC-defined) occurred in 0.3% (4/1,172), 0.3% (4/1,169) and 0.3% (3/1173) of patients, respectively (logrank-P=0.70 for both main comparisons).
“The one-year results of BIO-RESORT show that treatment with two very thin-strut biodegradable polymer stents and the thin strut durable polymer zotarolimus-eluting stent was similarly efficacious and safe with excellent one-year clinical outcomes in a complex population of all-comers,” said Dr. von Birgelen. “The absence of a loss of one-year safety and efficacy with the use of these biodegradable polymer-coated stents is a prerequisite before assessing their potential longer-term benefits.”
The BIORESORT trial was funded by research grants from Biotronik, Boston Scientific, and Medtronic. Dr. von Birgelen disclosed institutional research grants from AstraZeneca, Biotronik, Boston Scientific, and Medtronic.
About CRF and TCT
The Cardiovascular Research Foundation (CRF) is a nonprofit research and educational organization dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For over 25 years, CRF has helped pioneer innovations in interventional cardiology and has educated doctors on the latest treatments for heart disease.
Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine. Now in its 28th year, TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field.
For more information, visit www.crf.org and www.tctconference.com.